Roivant Sciences Quarterly Balance Sheet
NASDAQ: ROIVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Roivant Sciences financial position
As of Jun 30, 2026, Roivant Sciences reported total assets of $5.31 billion, up 5.4% from a year earlier against total liabilities of $384.6 million. Shareholders' equity stood at $4.23 billion, or 79.7% of assets. The company held $1.25 billion in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 16.72, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Roivant Sciences balance sheet (quarterly)
| Quarter (USD) | Q1 20262026-06-30 | Q4 20252026-03-31 | Q3 20252025-12-31 | Q2 20252025-09-30 | Q1 20252025-06-30 | Q4 20242025-03-31 | Q3 20242024-12-31 | Q2 20242024-09-30 | Q1 20242024-06-30 | Q4 20232024-03-31 | Q3 20232023-12-31 | Q2 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 1.25B | 1.42B | 1.48B | 1.24B | 1.24B | 2.72B | 1.99B | 1.96B | 5.68B | 6.49B | 6.67B | 1.41B |
| Short-Term Investments | 2.59B | 2.87B | 3.05B | 3.15B | 3.26B | 2.17B | 3.16B | 3.43B | — | 0 | — | — |
| Receivables | — | — | — | — | — | — | 678.00K | 1.92M | 79.79M | 3.99M | 41.08M | 52.12M |
| Inventory | — | — | — | — | — | — | — | — | 34.00M | 35.25M | 5.24M | 4.91M |
| Total Current Assets | 4.74B | 5.17B | 4.66B | 4.51B | 4.62B | 5.00B | 5.36B | 5.80B | 6.00B | 6.73B | 6.81B | 1.55B |
| Property, Plant & Equipment | 11.32M | 11.99M | 13.45M | 25.67M | 14.87M | 12.06M | 13.56M | 13.67M | 17.84M | 15.32M | 21.86M | 24.48M |
| Intangible Assets | — | — | — | — | — | — | — | — | 136.01M | 137.84M | 150.41M | 140.62M |
| Total Assets | 5.31B | 5.71B | 5.23B | 5.06B | 5.03B | 5.44B | 5.79B | 6.21B | 6.50B | 7.22B | 7.31B | 2.07B |
| Accounts Payable | 25.08M | 18.00M | 13.29M | 15.06M | 11.55M | 23.69M | 23.71M | 25.13M | 27.74M | 14.03M | 35.23M | 44.12M |
| Short-Term Debt | — | — | — | — | — | — | — | — | 12.00M | 12.00M | 45.71M | 49.00M |
| Total Current Liabilities | 283.60M | 281.24M | 151.96M | 133.86M | 113.87M | 149.41M | 141.48M | 556.25M | 215.04M | 266.76M | 244.90M | 265.55M |
| Long-Term Debt | — | — | — | — | — | — | — | — | 311.72M | 430.59M | 403.34M | 389.44M |
| Total Liabilities | 384.62M | 416.27M | 251.14M | 257.14M | 216.70M | 249.74M | 256.38M | 625.99M | 601.16M | 773.95M | 728.10M | 739.91M |
| Shareholders' Equity | 4.23B | 4.53B | 4.27B | 4.36B | 4.35B | 4.69B | 5.19B | 5.15B | 5.44B | 5.97B | 6.09B | 948.53M |
| Retained Earnings | -900.35M | -501.81M | -695.00M | -429.11M | -315.59M | 116.06M | 460.40M | 395.58M | 671.47M | 576.17M | 727.29M | -4.37B |
| Total Debt | — | — | — | — | — | — | — | — | 323.72M | 442.59M | 449.04M | 438.44M |
| Net Cash (Debt) | 3.84B | 4.29B | 4.53B | 4.39B | 4.50B | 4.89B | 5.15B | 5.39B | 5.35B | 6.05B | 6.22B | 969.79M |
| Shares Outstanding | 722.67M | 720.35M | 709.69M | 689.70M | 682.23M | 695.94M | 719.63M | 733.33M | 739.05M | 806.68M | 804.89M | 800.79M |
This table shows 12 quarterly periods of Roivant Sciences's balance sheet, from Q1 2026 back to Q2 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ROIV's reporting calendar. What is a balance sheet?